metastatic prostate cancer

  • July 22, 2024  

    How an Expert Would Manage His Own Advanced Prostate Cancer: An Update

    With: Marc B. Garnick, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »

  • June 14, 2022  

    How an Expert Would Manage His Own Advanced Prostate Cancer

    With: Marc B. Garnick, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »

  • April 20, 2022  

    Triplet Combination Improves Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer Bookmark

    George Lundberg, MD

    Metastatic carcinoma of the prostate is fatal, but a 3-drug combination treatment can prolong life substantially, according to new clinical trial results outlined by The ASCO Post.

    .

  • August 15, 2020  

    New Focus on ADT in Prostate Cancer Guideline Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Hormone therapy has been a mainstay in the treatment of metastatic prostate cancer. But, until now, guidelines have been short on detail. This news story outlines 38 approved additions to guidelines.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 5, 2018  

    Deadly Subtype Makes Up 17% of Metastatic Prostate Cancers Bookmark

    Emma Shtivelman, PhD

    Excerpt from Healio:

    “Treatment-emergent small cell neuroendocrine prostate cancer, a particularly deadly subtype of the disease, occurs in nearly one-fifth of all cases of metastatic, castration-resistant prostate cancer, study data showed.

    “Researchers suggested that the subtype should be treated with novel targeted therapies that are currently in the development or testing phase.”

    Go to full article published by Healio on July 9, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • June 11, 2018  

    Abiraterone May Be More Effective in Black Men With Prostate Cancer Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “Black men with metastatic castration-resistant prostate cancer (CRPC) who received hormonal therapy with the adrenal inhibitor abiraterone had greater and longer-lasting responses compared with white men, according to the results of a late-breaking study (abstract LBA5009) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago June 1–5.

    “The prospective study found that black men were more likely to have a decline in prostate-specific antigen (PSA) and had a longer median time to PSA worsening than white men. The findings were presented by Daniel George, MD, professor of medicine and surgery at Duke University.”

    Go to full article published by Cancer Network on Jun 2, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.